Home/Pipeline/DE-130 (STN-101)

DE-130 (STN-101)

Dry Eye Disease

Phase 2Active

Key Facts

Indication

Dry Eye Disease

Phase

Phase 2

Status

Active

Company

Santen Pharmaceutical

About Santen Pharmaceutical

Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.

View full company profile

Therapeutic Areas

Ophthalmology Eye Care

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
Elate Ocular®	Cambium Bio	Phase 3	Active
OT-301	Ocumension Therapeutics	Phase 2	Active
Avarept® Ophthalmic suspension 0.3%	Senju Pharmaceutical	Approved	Active
Dry Eye Care Portfolio	YD Bio	Commercial	Active
Dry Eye Studies	Oculus Research	Not Applicable (Service Provider)	Active
MediPrint Lens (Dry Eye)	MediPrint Ophthalmics	Pre-clinical/Research	Active
Tivanisiran	Sylentis	Phase 2/3	Active
A197	Aramis Biosciences	Phase 2	Active
KM102	Theratome Bio	Pre-clinical	Active
iTEAR®100 Commercialization	Olympic Ophthalmics	Commercial	Active
HydraD	EyeD Pharma	Pre-Clinical	Active
ST-100 (Vezocolmitide)	Stuart Therapeutics	Phase 3	Active